Last reviewed 2026-05-15 · How we verify

Etimid (BEMEGRIDE)

Phase 2 active Small molecule

Etimid (generic name: BEMEGRIDE) is a bemegride drug. It is currently in Phase 2 development.

Bemegride works by stimulating the central nervous system to increase the activity of neurotransmitters.

Etimid (Bemegride) is a small molecule drug in the bemegride class, originally developed by an unknown entity and currently owned by an unknown entity. Its target and exact mechanism of action are unclear, but it is used to treat certain conditions. The commercial status of Etimid is unknown, and it is not clear if it is patented or available as a generic medication. Key safety considerations are not well-documented. Further research is needed to fully understand Etimid's properties and uses.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	BEMEGRIDE
Drug class	bemegride
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Imagine your brain is a city with many different neighborhoods, each with its own unique function. Bemegride is like a loudspeaker that broadcasts a signal to the entire city, increasing the activity of the different neighborhoods and helping to restore balance to the brain's functions.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Etimid CI brief — competitive landscape report
Etimid updates RSS · CI watch RSS

Frequently asked questions about Etimid

What is Etimid?

Etimid (BEMEGRIDE) is a bemegride drug.

How does Etimid work?

Bemegride works by stimulating the central nervous system to increase the activity of neurotransmitters.

What is the generic name of Etimid?

BEMEGRIDE is the generic (nonproprietary) name of Etimid.

What drug class is Etimid in?

Etimid belongs to the bemegride class. See all bemegride drugs at /class/bemegride.

What development phase is Etimid in?

Etimid is in Phase 2.

Drug class: All bemegride drugs
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing